FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2898032890> ?p ?o ?g. }

• W2898032890 endingPage "420" @default.
• W2898032890 startingPage "414" @default.
• W2898032890 abstract "Because practice-based data on the usage of idarucizumab for urgent dabigatran reversal is unavailable, we evaluated the appropriateness of idarucizumab usage, its haemostatic effectiveness and clinical outcomes. An observational cohort study was performed including consecutive patients who were treated with idarucizumab between 2016 and 2018. Appropriate usage was assessed with predefined criteria. Post-reversal effectiveness was evaluated according to International Society on Thrombosis and Haemostasis (ISTH) recommendations. Patients were followed for 90 days for occurrence of thromboembolism, (re-)bleeding and death. Idarucizumab was used in 88 patients, of whom 53 (60%) presented with severe bleeding (20 gastrointestinal and 18 intracranial) and 35 (40%) requiring urgent surgical intervention. Use of idarucizumab was judged inappropriate in 25 patients (28%). Effective haemostasis was achieved in 32 of 48 (67%) bleeding patients in whom assessment was possible. Seven of 16 patients with major bleeding who did not achieve effective haemostasis (five intracranial) died, compared with two of 32 patients with effective haemostasis (relative risk 7.0, 95% confidence interval 1.6–30). Four patients (4.2%) developed thromboembolism [2 (2.1%) within 30 days] and four patients (4.2%) re-bleeding, all within 10 days. Seventeen patients (19%) died; 10 (11%) within 5 days. In this practice-based cohort, idarucizumab use was considered inappropriate in 28% of patients. Effective haemostasis was achieved in two-third of bleeding patients and was associated with lower mortality risk. Clinical outcomes were similar to those observed in the RE-VERSE AD trial, comprising re-bleeds and thromboembolism, and a high-mortality rate." @default.
• W2898032890 created "2018-10-26" @default.
• W2898032890 creator A5014965698 @default.
• W2898032890 creator A5026613773 @default.
• W2898032890 creator A5037319738 @default.
• W2898032890 creator A5049532218 @default.
• W2898032890 creator A5056110538 @default.
• W2898032890 creator A5057323541 @default.
• W2898032890 creator A5062603116 @default.
• W2898032890 creator A5065613978 @default.
• W2898032890 creator A5069096181 @default.
• W2898032890 creator A5073790407 @default.
• W2898032890 creator A5083604090 @default.
• W2898032890 creator A5090296015 @default.
• W2898032890 date "2018-10-17" @default.
• W2898032890 modified "2023-09-26" @default.
• W2898032890 title "Performance of idarucizumab as antidote of dabigatran in daily clinical practice" @default.
• W2898032890 cites W1971941179 @default.
• W2898032890 cites W1998433401 @default.
• W2898032890 cites W2034607173 @default.
• W2898032890 cites W2100677075 @default.
• W2898032890 cites W2113446992 @default.
• W2898032890 cites W2113561246 @default.
• W2898032890 cites W2136489990 @default.
• W2898032890 cites W2198635349 @default.
• W2898032890 cites W2509795914 @default.
• W2898032890 cites W2514338974 @default.
• W2898032890 cites W2586146752 @default.
• W2898032890 cites W2600746606 @default.
• W2898032890 cites W2734827407 @default.
• W2898032890 cites W2750504927 @default.
• W2898032890 cites W2989714602 @default.
• W2898032890 cites W3171831654 @default.
• W2898032890 cites W4254642512 @default.
• W2898032890 cites W2738499268 @default.
• W2898032890 doi "https://doi.org/10.1093/europace/euy220" @default.
• W2898032890 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30339226" @default.
• W2898032890 hasPublicationYear "2018" @default.
• W2898032890 type Work @default.
• W2898032890 sameAs 2898032890 @default.
• W2898032890 citedByCount "28" @default.
• W2898032890 countsByYear W28980328902019 @default.
• W2898032890 countsByYear W28980328902020 @default.
• W2898032890 countsByYear W28980328902021 @default.
• W2898032890 countsByYear W28980328902022 @default.
• W2898032890 countsByYear W28980328902023 @default.
• W2898032890 crossrefType "journal-article" @default.
• W2898032890 hasAuthorship W2898032890A5014965698 @default.
• W2898032890 hasAuthorship W2898032890A5026613773 @default.
• W2898032890 hasAuthorship W2898032890A5037319738 @default.
• W2898032890 hasAuthorship W2898032890A5049532218 @default.
• W2898032890 hasAuthorship W2898032890A5056110538 @default.
• W2898032890 hasAuthorship W2898032890A5057323541 @default.
• W2898032890 hasAuthorship W2898032890A5062603116 @default.
• W2898032890 hasAuthorship W2898032890A5065613978 @default.
• W2898032890 hasAuthorship W2898032890A5069096181 @default.
• W2898032890 hasAuthorship W2898032890A5073790407 @default.
• W2898032890 hasAuthorship W2898032890A5083604090 @default.
• W2898032890 hasAuthorship W2898032890A5090296015 @default.
• W2898032890 hasBestOaLocation W28980328902 @default.
• W2898032890 hasConcept C126322002 @default.
• W2898032890 hasConcept C12770488 @default.
• W2898032890 hasConcept C141071460 @default.
• W2898032890 hasConcept C168563851 @default.
• W2898032890 hasConcept C23131810 @default.
• W2898032890 hasConcept C2776301958 @default.
• W2898032890 hasConcept C2776413415 @default.
• W2898032890 hasConcept C2778810321 @default.
• W2898032890 hasConcept C2779161974 @default.
• W2898032890 hasConcept C2779365888 @default.
• W2898032890 hasConcept C2909408951 @default.
• W2898032890 hasConcept C29730261 @default.
• W2898032890 hasConcept C44249647 @default.
• W2898032890 hasConcept C71924100 @default.
• W2898032890 hasConcept C72563966 @default.
• W2898032890 hasConceptScore W2898032890C126322002 @default.
• W2898032890 hasConceptScore W2898032890C12770488 @default.
• W2898032890 hasConceptScore W2898032890C141071460 @default.
• W2898032890 hasConceptScore W2898032890C168563851 @default.
• W2898032890 hasConceptScore W2898032890C23131810 @default.
• W2898032890 hasConceptScore W2898032890C2776301958 @default.
• W2898032890 hasConceptScore W2898032890C2776413415 @default.
• W2898032890 hasConceptScore W2898032890C2778810321 @default.
• W2898032890 hasConceptScore W2898032890C2779161974 @default.
• W2898032890 hasConceptScore W2898032890C2779365888 @default.
• W2898032890 hasConceptScore W2898032890C2909408951 @default.
• W2898032890 hasConceptScore W2898032890C29730261 @default.
• W2898032890 hasConceptScore W2898032890C44249647 @default.
• W2898032890 hasConceptScore W2898032890C71924100 @default.
• W2898032890 hasConceptScore W2898032890C72563966 @default.
• W2898032890 hasIssue "3" @default.
• W2898032890 hasLocation W28980328901 @default.
• W2898032890 hasLocation W28980328902 @default.
• W2898032890 hasLocation W28980328903 @default.
• W2898032890 hasLocation W28980328904 @default.
• W2898032890 hasOpenAccess W2898032890 @default.
• W2898032890 hasPrimaryLocation W28980328901 @default.
• W2898032890 hasRelatedWork W2049288272 @default.

• next